Edition:
United States

Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Jun 21 2018

Key marijuana drug approval looms as cannabis goes mainstream

LONDON Evidence that cannabis can ease epilepsy and other conditions is building as a British company counts down to what would be the first U.S. government approval for a prescription drug derived from the marijuana plant.

Jun 20 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

Jun 19 2018

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

ZURICH/LONDON Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.

May 31 2018

Another antibiotic crisis - fragile supply leads to shortages

LONDON Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fuelling the evolution of "superbugs" that do not respond to modern medicines, according to a new report on Thursday.

May 31 2018

Another antibiotic crisis: fragile supply leads to shortages

LONDON Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fuelling the evolution of "superbugs" that do not respond to modern medicines, according to a new report on Thursday.

May 30 2018

Gap in regulating biotech drug copies prompts WHO to step in

LONDON Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike - but uneven regulation has created a lopsided market.

May 24 2018

U.S. biotechs to speed work on Nipah vaccine as virus hits India

LONDON A global coalition set up a year ago to fight epidemics has struck a $25 million deal with two U.S. biotech companies to accelerate work on a vaccine against the brain-damaging Nipah virus that has killed 12 people in India.

May 23 2018

Why the world needs more than one Ebola vaccine

LONDON - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck - seems bound to win.

May 21 2018

Roche drug dramatically reduces bleeds in key hemophilia tests

LONDON Roche's new hemophilia drug Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position.

May 18 2018

Regulators flag possible birth defect link to GSK's HIV drug

LONDON U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary